Edgewise Therapeutics

CompanyUnited States

Edgewise Therapeutics develops one asset, in phase 2 (EDG-15400 in heart failure with preserved ejection fraction). Mostly small molecule; based in the United States.

1
Asset
Furthest stage: Phase 2; 1
Trial: 1
Signal

Pipeline

1

EDG-15400
Selective cardiac sarcomere modulator designed to treat heart failure with preserved ejection fraction
Phase 2, Small molecule, heart failure with preserved ejection fraction, HFpEF

Full company profiles: pipeline, trials, funding and people.

In the full profile

Trials1
Signals1
Similar companies6